The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes
Open accessAbstract
Inclusion of continuous glucose monitoring (CGM) targets for children, adolescents, and young adults <25 years. Adoption of a unified fingerstick capillary glucose (SMBG) target of between 4 and 10 mmol/L (70–180 mg/dl), which aligns with the target CGM time in range (TIR), while emphasizing a tighter fasting target range of 4–8 mmol/L (70–144 mg/dl). Recognition that disparities in the social determinants of health (SDOH) and inequitable access to modern diabetes therapies represent significant barriers to achieving glucose targets and optimizing clinical outcomes. Health stakeholders are responsible for addressing this disparity. Achieving target glucose levels assessed through CGM, HbA1c, and/or SMBG: Target HbA1c for young people with diabetes should be <53 mmol/mol (<7.0%) A CGM metrics, recorded over a 14-day period, should have time spent as follows: B Less stringent HbA1c, CGM, or SMBG targets are only advisable when achieving the standard target is assessed as being detrimental to the overall well-being of the person with diabetes or their caregivers. Factors to consider when setting a less stringent target include (but are not limited to): Glycemic targets for young people with diabetes are needed as optimizing glycemia reduces short and long-term complications.1, 2 In addition to protecting against micro- and macrovascular complications, of particular importance in pediatrics is the negative association of hypoglycemia and hyperglycemia on cognition and brain structure,3 especially in individuals with early onset diabetes.4 Further, the wider impact of diabetes on healthcare systems and health economics is an important driver to target better glycemic outcomes to prevent future complications.5, 6 Diabetes registries have shown steady improvement in median HbA1c levels in recent decades, yet only a minority of young people attain current glycemic targets.7 The improvements that have been demonstrated can be attributed to multiple factors, including how healthcare teams set and communicate glycemic targets, improved therapeutics (insulin analogs, CGM), highly skilled and knowledgeable workforce, and, recently, the use of automated insulin delivery systems. Nevertheless, social determinants of health, pediatric diabetes workforce constraints, and access to improved therapeutics remain significant barriers preventing more young people from reaching target glycemia, and further, drives health inequity.8, 9 Setting glycemic targets has been standard practice for diabetes organizations, including ISPAD, the American Diabetes Association (ADA), and the National Institute of Clinical Excellence (NICE) in the United Kingdom for 20 years, and have been regularly updated when evidence has supported change.10 For example, when different stakeholders published divergent HbA1c targets, and lower HbA1c targets were shown not to increase the rates of severe hypoglycemia,11 lower targets were adopted. It is important to recognize that setting targets contributes to improving glycemia as shown by the observation that a combination of setting a lower target HbA1c and consistency among members of teams within centers is associated with lower center HbA1c levels.11, 12 It is essential that target setting is a collaborative discussion with the person with diabetes (including caregivers) and health care professionals. Furthermore, prospective audit activity, involvement in data registries, and clinical benchmarking, including quality improvement implementation, are also associated with overall improvements in glycemic outcomes.13, 14 Health care professionals and people with diabetes now have a wide array of tools to assess glycemia, including self-monitored capillary blood glucose (SMBG) values, HbA1c, and CGM. While traditionally HbA1c has been the gold standard, there are limitations to this measurement as discussed later. Correspondingly, with rapidly increasing adoption of CGM, which arguably avoids these limitations, CGM metric reporting has been standardized and CGM metrics are included in this chapter. The recent COVID-19 global pandemic, and increased opportunities for the use of video or phone appointments between a person with diabetes and/or their carer and the health care professional, has highlighted the utility of CGM metrics to assess glycemia when laboratory measurement of HbA1c level is not available. While disparities also exist for accessing telemedicine including implicit bias, well-developed work plans can expand the population who can benefit from this health delivery method.15 Nevertheless, not all young people can access CGM and are reliant on SMBG and/or HbA1c measurement. Using all available forms of glycemic data, in combination if available, will give the most accurate account of glycemia to help guide therapy. Individualized glycemic target setting above the stated HbA1c target has been emphasized in recent consensus statements.16, 17 This was included to address concerns that for some youn
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Social determinants of health and diabetes: A scientific review
Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2021) · Diabetes Care · doi:10.2337/dci20-0053 · Cited by 1,732
Reichard, P., Nilsson, B.-Y., & Rosenqvist, U. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290502 · Cited by 1,202
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793
The Clinical Information Value of the Glycosylated Hemoglobin Assay
Nathan, D. M., Singer, D. E., Hurxthal, K., & Goodson, J. D. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402093100602 · Cited by 706
DiMeglio, L. A., Acerini, C. L., Codner, E., Craig, M. E., Hofer, S. E., Pillay, K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12737 · Cited by 604
Self-citationDiabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Cited by
Halperin, I. J., Wicklow, B., Amed, S., Chambers, A., Courage, C., Cummings, E., Kirkland, P., MacKay, D., Nakhla, M., Punthakee, Z., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.001 · Cited by 22
Metadata
- Authors
- de Bock, M., Codner, E., Craig, M. E., Huynh, T., Maahs, D. M., Mahmud, F. H., Marcovecchio, L., & DiMeglio, L. A.
- Venue
- Pediatric Diabetes
- Publisher
- Wiley
- Published
- 2022-12
- Volume
- 23
- Issue
- 8
- Pages
- 1270-1276
- ISSN
- 1399-543X (ISSN-L)
- 1399-5448
- OpenAlex
- W4312179373
- Cited by
- 254
- References
- 51
- FWCI
- 29.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. https://app.cochat.ai/papers/10.1111/pedi.13455
- The paper
- de Bock, M., Codner, E., Craig, M. E., Huynh, T., Maahs, D. M., Mahmud, F. H., Marcovecchio, L., & DiMeglio, L. A. (2022). ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatric Diabetes. https://doi.org/10.1111/pedi.13455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.